Search Results 411-420 of 18017 for Alopecia

1. A Study to Evaluate IMGN632 with Venetoclax and/or Azacitidine to Treat Patients with CD123-Positive Acute Myeloid Leukemia - Mayo Clinic

   Previous treatment-related toxicities must have resolved to Grade 1 or baseline (excluding alopecia). Total white blood cell count must be less than 25 × 10 ...

2. Publications - Tufia C. Haddad, M.D. - Mayo Clinic

   ... alopecia in breast cancer. Support Care Cancer. 2024 Jun 6; 32 (7):412 Epub 2024 June 06. View PubMed; Haemmerle R, Paludo J, Haddad TC, Pritchett JC. The ...

3. Hydrochlorothiazide (oral route) - Side effects & dosage - Mayo Clinic

   Hydrochlorothiazide is also used to treat fluid retention (edema) that is caused by congestive heart failure, severe liver disease (cirrhosis), kidney disease, ...

4. Betamethasone dipropionate (topical application route) - Side effects & dosage - Mayo Clinic

   Betamethasone topical cream, gel, lotion, and ointment are used to help relieve redness, itching, swelling, or other discomforts caused by certain skin ...

5. A Study of Response, Survival, Safety, and Tolerability of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer - Mayo Clinic

   ... alopecia, and irreversible late sequelae of radiation therapy, must have resolved to Grade 0 or 1 per Common Terminology Criteria for Adverse Events (CTCAE ...

6. Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer

   Patients with any grade of alopecia are allowed to enter the study. Patients must have adequate organ function; ECOG performance status (PS) of 0 or 1 ...

7. A Study to Evaluate T-DM1 With or Without Abemaciclib in Women and Men with HER2-positive Advanced or Metastatic Breast Cancer - Mayo Clinic

   NOTE: All residual toxicities (except alopecia) should be at baseline or grade 1 (including peripheral neuropathy). NOTE: If indicated, patients can ...

8. Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). - Mayo Clinic

   Patients with vitiligo or alopecia;; Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement or psoriasis not ...

9. CATALINA-2: A Clinical Study Of TORL-1-23 In Platinum-resistant Ovarian Cancer.

   ... alopecia or laboratory abnormalities otherwise meeting eligibility requirements. 2. Participants with clear cell, mucinous, sarcomatous (including ...

10. A Study to Evaluate Pemetrexed and Pembrolizumab to Treat Recurrent and/or Metastatic Salivary Gland Malignancies - Mayo Clinic

    Participation eligibility · Exceptions: Neuropathy, fatigue, and/or alopecia may be Grade 1. · Known active central nervous system (CNS) metastases. NOTE: ...